Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab - Seite 2
About Sema4
Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment,
and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the
areas of reproductive health and oncology. Centrellis, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and
to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.
Lesen Sie auch
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking statements, including without limitation, Sema4’s performance under the agreement to utilize Sema4’s advanced genomic testing
to identify patients with tumors harboring NRG1 gene fusions, who may be eligible for investigational treatment with Zeno in the eNRGy trial; the companies’ plan to support
access to next-generation sequencing for eligible patients and raise awareness of Merus’ eNRGy clinical trial; the opportunity to leverage Sema4’s
advanced genomic testing solutions for oncology, and its promise to help accelerate enrollment in the eNRGy trial; the potential for Zeno to become an effective new
treatment option for patients with cancers harboring NRG1 fusions; the design and treatment potential for Zeno and its mechanism of action and potential to be particularly effective
against NRG1+ cancers; the Zeno clinical study design, and occurrence of NRG1 fusion cancers. These forward-looking statements are based on management’s current expectations. These statements are
neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding,
which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics, Triclonics
and multispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate
revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs;
potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for
those third parties to not perform satisfactorily; impacts of the COVID-19 pandemic; we may not identify suitable Biclonics or bispecific antibody candidates under our collaborations or
our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development
and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to
comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.